TAO Synergies (TAOX) Accumulated Expenses (2019 - 2026)
TAO Synergies' (TAOX) quarterly Accumulated Expenses came in at $132444.0 in Q2 2026, up 100.36% on a YoY basis from $66104.0 in Q2 2025, and down 15.86% quarter-over-quarter from $157416.0 in Q1 2026.
Analysis
TAO Synergies (TAOX) Accumulated Expenses (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Accumulated Expenses for 8 consecutive years, with $132444.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Accumulated Expenses rose 100.36% year-over-year to $132444.0; the trailing twelve-month figure through Jun 2026 stood at $132444.0 (up 100.36% YoY), and the FY2025 full-year result was $638516.0, down 8.39% from the prior year.
- Accumulated Expenses slipped to $132444.0 in Q2 2026 per TAOX's latest filing, from $157416.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $8.8 million in Q2 2024 and bottomed at $54542.0 in Q3 2024.
- Historically, Accumulated Expenses has averaged $1.3 million across 5 years, with a median of $306551.5 in 2022.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 12858.83% in 2024, then tumbled 99.25% in 2025.
- Over 5 years, Accumulated Expenses stood at $536714.0 in 2022, then fell by 18.79% to $435891.0 in 2023, then surged by 59.9% to $696980.0 in 2024, then slipped by 8.39% to $638516.0 in 2025, then plunged by 79.26% to $132444.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $132444.0, $157416.0, and $638516.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 132,444.00 |
| Mar 31, 2026 | 157,416.00 |
| Dec 31, 2025 | 638,516.00 |
| Sep 30, 2025 | 92,396.00 |
| Jun 30, 2025 | 66,104.00 |
| Mar 31, 2025 | 96,484.00 |
| Dec 31, 2024 | 696,980.00 |
| Sep 30, 2024 | 54,542.00 |
| Jun 30, 2024 | 8.83 Mn |
| Mar 31, 2024 | 6.02 Mn |
| Dec 31, 2023 | 435,891.00 |
| Sep 30, 2023 | 1.53 Mn |
| Jun 30, 2023 | 68,137.00 |
| Mar 31, 2023 | 3.40 Mn |
| Dec 31, 2022 | 536,714.00 |
| Sep 30, 2022 | 200,205.00 |
| Jun 30, 2022 | 345,114.00 |
| Mar 31, 2022 | 267,989.00 |
| Dec 31, 2021 | 698,406.00 |
| Sep 30, 2021 | 71,953.00 |